This study shows citalopram reduces hepatocellular carcinoma by modulating C5aR1+ tumor-associated macrophages and enhancing CD8+ T cell anti-tumor immunity.

eLife · Feb 9, 2026Peer-reviewedCancer Biology

SSRI antidepressant citalopram reverses the Warburg effect to inhibit hepatocellular carcinoma by directly targeting GLUT1

Fangyuan Dong, Kang He, Shan Zhang, Kaiyuan Song, Luju Jiang, Li-Peng Hu, Qing Li, Xueli Zhang, Naiqi Zhang, Bo-Tai Li, L.-L. Zhu, Jun Li, Mingxuan Feng, Yunchen Gao, Jie Chen, , Shu‐Heng Jiang

This study identifies GLUT1 as a target of SSRIs, showing citalopram inhibits HCC by reversing the Warburg effect through GLUT1 antagonism.

Cell Reports · Oct 1, 2024Peer-reviewedCancer Biology

A survey of optimal strategy for signature-based drug repositioning and an application to liver cancer

Chen Guang Yang, Hailin Zhang, Mengnuo Chen, Siying Wang, Ruolan Qian, Linmeng Zhang, Xiaowen Huang, Jun Wang, Zhicheng Liu, Wenxin Qin, Cun Wang, Hualian Hang, Hui Wang

This study identifies an optimal strategy for drug repositioning using LINCS data and applies it to discover new therapeutics for liver cancer, showing homoharringtonine as a promising candidate.

eLife · Feb 18, 2022Peer-reviewedBioinformatics